The Coronavirus is one of the fastest spreading viruses that has caused a pandemic and affected almost the entire world. The Coronavirus essentially originates from the family of viruses that are known to lead to illnesses like common cold, flu, middle east respiratory syndrome and severe acute respiratory syndrome. One of the new viruses that was recently discovered is the coronavirus2 (SARS – COV- 2) and the disease caused by this virus is known as COVID -19.
The services provided by GeneMedi
The GeneMedi was founded in the year 2010 and it is a biotech company that has high expertise in the viral vectors of the transfer in mediated gene, gene therapy and the gene editing. The professionals from GeneMedi provide assistance to the scientists from vector optimization to the academic and also provide help in process development, technology transfer and scalable production.
In terms of the company’s offerings, GeneMedi provides professional service of packaging technology related to adenovirus, lentivirus and adeno-associated virus (AAV). The different recombinant viral systems of packaging are created for the customers. The viruses from the GeneMedi are inspected and tested for ensuring high quality and excellent purity. The viral vectors that are produced by GeneMedi are fit for usage in both the vivo and vitro thereby meeting the maximum demands from the clients and customers. The GeneMedi has also manufactured and launched a large number of the human full length protein coding ORF cDNA clones in the way of various sets for vector systems that come with multiple features that make the clones fit for numerous functional assays, easy purification in cell types, translation coupling systems and cell free transcription and proteomics study and wide scale functional genomics.
You can check out https://www.genemedi.net/ for more information on the different packages as well as services provided by the GeneMedi.
Things to know about recombinant Coronavirus antigens
The recombinant antigens reagents are called by multiple names that include COVID-19 protein, Coronavirus protein and COVID-19 antigens. The COVID-19 is essentially a novel category of pathogenic Coronavirus induced disease which first originated in China and subsequently has expanded quickly across the globe. The GeneMedi is responsible for producing various types of recombinant 2019 nCoV antigens that includes Recombinant Nucleocapsid, Envelope E Protein, 3C like Proteinase, Spike RBD protein, Spike protein – S1 protein and Spike protein (S Protein S1 + S2 ECD). The recombinant proteins related to the Coronavirus such as COVID-19 proteins, 2019 nCOV proteins and Coronavirus proteins were expressed in the types of expression systems like mammalian (human cells, HEK293), baculovirus-insect cells and E-Coli. The recombinant proteins belonging to Coronavirus 2019 or the COVID 19 are apt or appropriate immunogens for the lateral flow tests, functional ELISA as well as other immunoassays.
In the global efforts of developing the effective diagnosis as well as drug against the 2019 nCOV, called SARS2 Coronavirus the scientists of the GeneMedi are continuing their efforts and providing all co-operation for positive outcome.
Comparison between SARS-CoV and COVID-19 in pathogens and pathology
The novel Coronavirus pneumonia which is caused by the novel Coronavirus was named COVID-19 by the World Health Organization (WHO) in the recent times and this virus emerged in the Wuhan region of China during the December of 2019. The novel Coronavirus Pneumonia (NCP) subsequently broke out and spread aggressively following the movement of people from Wuhan to different parts of the globe.
The various Coronaviruses are responsible for causing the light respiratory disease amongst the human beings. However in contrasting comparison the SARS CoV that was first found in the year 2003 in China and the MERS-CoV in the year 2016, both of which were found to be hosted by the bats and eventually resulted in transmitting from the animals to humans leading to the severe form of respiratory diseases respectively.
Some of the conclusions of the comparison between COVID-19 and SARS-CoV can be found as follows. The older patients are found to have higher Case Fatality Rate (CFR) than the young people. The males have a higher degree of CFR in comparison to the females however this is likely to converge with the increase in age. The COVID-19 infection might eventually show kidney as well as testis damage. This in combination with the higher rate of CFR in the male population, the disorder of the genitourinary system caused by infection of COVID-19 needs proper caution.
It is vital that we should control CRS in the NCP IL-6, IL-10 and their receptors might be potential drugable target. Consistent with the decrease of CD+4 T and the CD+8T cells, the lymphocyte depletion and spleen damage might exist in the NCP patients. The various approaches for T Cell rescued could be considered. The other receptors like DC-Sign and L-Sign must be investigated in future.